{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000125","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.293239+00:00","generated_at":"2026-06-08T19:02:50.930363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MacroGenics Q3 net income $17.6M ($0.28 EPS); cash $256.4M; TAMARACK enrollment ahead of schedule","bullets":["Net income $17.6M ($0.28 diluted EPS) vs net loss $24.8M in Q3 2022; revenue $10.4M down from $41.7M.","Cash and marketable securities $256.4M; expect cash runway into 2026; received $15.7M Gilead milestone and $50M Sanofi milestone in Q3.","Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule; data readout expected H1 2024.","Initiated LORIKEET Phase 2 of lorigerlimab in mCRPC; IND submitted for MGC026 ADC; Phase 1 to start Q1 2024.","R&D expenses $30.1M (down from $48.2M); SG&A $12.4M (down from $15.4M); shares outstanding 62.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000125","json":"https://secwatch.observer/filing/0001125345-23-000125.json","markdown":"https://secwatch.observer/filing/0001125345-23-000125.md","text":"https://secwatch.observer/filing/0001125345-23-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/0001125345-23-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/mgnx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:02:50.930363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c540b2bf25ba219db7a7769373b8d507813a6e0","claim":"MACROGENICS INC reported the quarter ended September 30, 2023 results: revenue $10.4 million.","evidence_excerpt":"Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/0001125345-23-000125-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}